ECSS
CORT icon

Eurizon Capital SGR SpA’s Corcept Therapeutics CORT Stock Holding History

Eurizon Capital SGR SpA’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Sell
1,722
-401
-19% -$24.2K ﹤0.01% 811
2026
Q1 		$82.1K Hold
2,123
– – ﹤0.01% 936
2025
Q4 		$135K Buy
+2,123
New +$167K ﹤0.01% 720

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's CORT Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Corcept Therapeutics (CORT) stake by 19% in Q2 2026, selling an estimated $24.2K and leaving 1,722 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #811.

Eurizon Capital SGR SpA first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Eurizon Capital SGR SpA held 1,722 shares of Corcept Therapeutics worth $151K as of Q2 2026.
  • Eurizon Capital SGR SpA sold 401 Corcept Therapeutics shares in Q2 2026, an estimated $24.2K.
  • Corcept Therapeutics made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #811 holding.
  • Eurizon Capital SGR SpA first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.